Precipio, Inc. (PRPO)
- Previous Close
7.70 - Open
7.70 - Bid 5.71 x 100
- Ask 7.69 x 100
- Day's Range
6.63 - 7.99 - 52 Week Range
3.90 - 10.74 - Volume
14,463 - Avg. Volume
12,474 - Market Cap (intraday)
10.124M - Beta (5Y Monthly) 1.04
- PE Ratio (TTM)
-- - EPS (TTM)
-2.93 - Earnings Date May 12, 2025 - May 16, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Precipio, Inc., a healthcare biotechnology company, provides cancer diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; and HemeScreen, a suite of robust genetic diagnostic panels. It offers biomarker testing and clinical project services to bio-pharma customers. Precipio, Inc. is based in New Haven, Connecticut.
www.precipiodx.com54
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: PRPO
View More
Performance Overview: PRPO
Trailing total returns as of 4/24/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PRPO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PRPO
View MoreValuation Measures
Market Cap
10.12M
Enterprise Value
9.99M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.53
Price/Book (mrq)
0.82
Enterprise Value/Revenue
0.54
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-23.15%
Return on Assets (ttm)
-15.02%
Return on Equity (ttm)
-32.35%
Revenue (ttm)
18.53M
Net Income Avi to Common (ttm)
-4.29M
Diluted EPS (ttm)
-2.93
Balance Sheet and Cash Flow
Total Cash (mrq)
1.39M
Total Debt/Equity (mrq)
10.36%
Levered Free Cash Flow (ttm)
1.7M